These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

674 related articles for article (PubMed ID: 37334366)

  • 1. Liver organoids: a promising three-dimensional model for insights and innovations in tumor progression and precision medicine of liver cancer.
    Chen Y; Liu Y; Chen S; Zhang L; Rao J; Lu X; Ma Y
    Front Immunol; 2023; 14():1180184. PubMed ID: 37334366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine.
    Pamarthy S; Sabaawy HE
    Mol Cancer; 2021 Sep; 20(1):125. PubMed ID: 34587953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening.
    Broutier L; Mastrogiovanni G; Verstegen MM; Francies HE; Gavarró LM; Bradshaw CR; Allen GE; Arnes-Benito R; Sidorova O; Gaspersz MP; Georgakopoulos N; Koo BK; Dietmann S; Davies SE; Praseedom RK; Lieshout R; IJzermans JNM; Wigmore SJ; Saeb-Parsy K; Garnett MJ; van der Laan LJ; Huch M
    Nat Med; 2017 Dec; 23(12):1424-1435. PubMed ID: 29131160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer organoid co-culture model system: Novel approach to guide precision medicine.
    Yuan J; Li X; Yu S
    Front Immunol; 2022; 13():1061388. PubMed ID: 36713421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Organoid Models for Precision Cancer Immunotherapy.
    Sun CP; Lan HR; Fang XL; Yang XY; Jin KT
    Front Immunol; 2022; 13():770465. PubMed ID: 35450073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor Organoids: The Era of Personalized Medicine.
    Rassomakhina NV; Ryazanova AY; Likhov AR; Bruskin SA; Maloshenok LG; Zherdeva VV
    Biochemistry (Mosc); 2024 Jan; 89(Suppl 1):S127-S147. PubMed ID: 38621748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Organoids: An intermediate modeling platform in precision oncology.
    Jin MZ; Han RR; Qiu GZ; Ju XC; Lou G; Jin WL
    Cancer Lett; 2018 Feb; 414():174-180. PubMed ID: 29174804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Organoids: approaches and utility in cancer research.
    Zhou B; Feng Z; Xu J; Xie J
    Chin Med J (Engl); 2023 Aug; 136(15):1783-1793. PubMed ID: 37365679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical tumor organoid models in personalized cancer therapy: Not everyone fits the mold.
    Hu LF; Yang X; Lan HR; Fang XL; Chen XY; Jin KT
    Exp Cell Res; 2021 Nov; 408(2):112858. PubMed ID: 34600901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Organoids: new frontiers in tumor immune microenvironment research.
    Yang Y; Cui J; Kong Y; Hou Y; Ma C
    Front Immunol; 2024; 15():1422031. PubMed ID: 39136020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in patient-derived liver cancer cell models: a step forward for precision medicine.
    Zhang Z; Hui L
    Acta Biochim Biophys Sin (Shanghai); 2023 Nov; 55(11):1707-1717. PubMed ID: 37766458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor organoids: applications in cancer modeling and potentials in precision medicine.
    Xu H; Jiao D; Liu A; Wu K
    J Hematol Oncol; 2022 May; 15(1):58. PubMed ID: 35551634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-derived cancer organoids for drug screening: Basic technology and clinical application.
    Ren X; Chen W; Yang Q; Li X; Xu L
    J Gastroenterol Hepatol; 2022 Aug; 37(8):1446-1454. PubMed ID: 35771719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Converging bioprinting and organoids to better recapitulate the tumor microenvironment.
    Wang X; Luo Y; Ma Y; Wang P; Yao R
    Trends Biotechnol; 2024 May; 42(5):648-663. PubMed ID: 38071145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-Dimensional Organoids in Cancer Research: The Search for the Holy Grail of Preclinical Cancer Modeling.
    Dzobo K; Rowe A; Senthebane DA; AlMazyadi MAM; Patten V; Parker MI
    OMICS; 2018 Dec; 22(12):733-748. PubMed ID: 30571609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in patient-derived tumor organoids for reconstructing TME of head and neck cancer.
    Chen L; Chen Y; Ge L; Zhang Q; Meng J
    J Oral Pathol Med; 2024 Apr; 53(4):238-245. PubMed ID: 38561906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-derived organoids in human cancer: a platform for fundamental research and precision medicine.
    Qu S; Xu R; Yi G; Li Z; Zhang H; Qi S; Huang G
    Mol Biomed; 2024 Feb; 5(1):6. PubMed ID: 38342791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Micro-Engineered Organoid-on-a-Chip Based on Mesenchymal Stromal Cells to Predict Immunotherapy Responses of HCC Patients.
    Zou Z; Lin Z; Wu C; Tan J; Zhang J; Peng Y; Zhang K; Li J; Wu M; Zhang Y
    Adv Sci (Weinh); 2023 Sep; 10(27):e2302640. PubMed ID: 37485650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-derived organoids as a model for tumor research.
    Wang J; Feng X; Li Z; Chen Y; Huang W
    Prog Mol Biol Transl Sci; 2022; 189(1):259-326. PubMed ID: 35595351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reconstructing the tumor architecture into organoids.
    Luo Z; Zhou X; Mandal K; He N; Wennerberg W; Qu M; Jiang X; Sun W; Khademhosseini A
    Adv Drug Deliv Rev; 2021 Sep; 176():113839. PubMed ID: 34153370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.